Biostatistics

Applications in Medicine

Nuno Sepúlveda, 18.11.2024

Syllabus

1. General review

- a. What is Biostatistics?
- b. Population/Sample/Sample size
- c. Type of Data quantitative and qualitative variables
- d. Common probability distributions
- e. Work example Malaria in Tanzania

2. Applications in Medicine

- a. Construction and analysis of diagnostic tools Binomial distribution, sensitivity, specificity, ROC curve,Rogal-Gladen estimator
- b. Estimation of treatment effects generalized linear models
- c. Survival analysis Weibull regression, Kaplan-Meier curve, log-rank test, Cox's proportional hazards model

3. Applications in Genetics, Genomics, and other 'omics data

- Genetic association studies Hardy-Weinberg test, homozygosity, minor allele frequencies, additive model, multiple testing correction
- b. Methylation association studies M versus beta values, estimation of biological age
- c. Gene expression studies based on RNA-seq experiments Tests based on Poisson and Negative-Binomial

4. Other Topics

- a. Estimation of Species diversity Diversity indexes, Poisson mixture models
- b. Serological analysis Gaussian (skew-normal) mixture models
- c. Advanced sample size and power calculations

Parametric analysis

versus

Non-parametric analysis

Parametric analysis



Non-parametric analysis



Non-parametric methods

Comparison of different survival curves

Log-rank test Peto-Peto test

Kolmogorov-Smirnov test

Semi-parametric regression

Cox's proportional hazard model

Comparison of different survival curves

Two treatments under comparison

Time to clinical response

$$H_0: S_1(t) = S_2(t)$$
 versus $H_0: S_1(t) \neq S_2$

Log-rank test as a Mantel-Haenszel test for categorical data

Do you know other tests

Mantel-Haenszel test

Analysis of the association in $K \times 2 \times 2$ contingency tables (an extension of Fisher's exact test to K tables 2×2).

Stratum	Treatment	Responded	Not Responded
1	Α		
	В		
2	Α		
	В		
3	Α		
	В		

In stratum i

$$\Delta_i = \frac{\pi_{1i}(1 - \pi_{2i})}{(1 - \pi_{1i})\pi_{2i}}$$

 π_{1i} = prob. of response to treatment 1

 π_{2i} = prob. of response to treatment 2

$$H_0: \Delta_1 = \cdots = \Delta_K = 1$$
 (t) versus $H_1: \exists_{i,j} \Delta_i \neq \Delta_j = 1$

under the assumption of $\Delta_1 = \cdots = \Delta_K = \Delta$

Log-rank test

Adaptation of the classical Mantel-Haenszel test for k x 2 x 2 contigency tables where k is the number of different timepoints in which it was observed the event of interest



Basic idea

There are k 2 x 2 tables like this one

Group	Number of "deaths" at $t_{(i)}$	Number of "survivors" beyond $t_{(i)}$	Total
1	d_{1i}	$n_{1i} - d_{1i}$	n_{1i}
2	d_{2i}	$n_{2i} - d_{2i}$	n_{2i}
Total	d_i	$n_i - d_i$	n_i

Conditional probalitity (see Fisher's exact test)

$$H_0: S_1(t) = S_2(t)$$
 versus $H_1: S_1(t) \neq S_2(t)$

$$H_0: \pi_{1i} = \pi_{2i} = \pi \text{ versus } H_1: \pi_{1i} \neq \pi_{2i}$$

 π_{1i} = probability of "death" at time $t_{(i)}$ in group 1

 π_{2i} = probability of "death" at time $t_{(i)}$ in group 2

$$d_{li} \mid \pi_{li}, n_{li} \rightsquigarrow \text{Binomial}(n = n_{li}, \pi = \pi_{li}), l = 1,2$$

$$d_i \mid \pi_{li}, n_{li}, H_0 \rightsquigarrow \text{Binomial}(n = n_i, \pi = \pi_i)$$

Basic idea

Calculate the distribution of d_{1i} conditional to the total marginals

Group	Number of "deaths" at $t_{(i)}$	Number of "survivors" beyond $t_{(i)}$	Total
1	a_{1i}	$n_{1i} - d_{1i}$	n_{1i}
2	d_{2i}	$n_{2i} - d_{2i}$	n_{2i}
Total	(a_i)	$n_i - d_i$	(n_i)

Conditional probability (see Fisher's exact test)

$$d_{1i} \mid d_i, n_i, n_{1i}, H_0 \Rightarrow$$
 Hypergeometric $(N = n_i, M = d_i, n = n_{1i})$

$$P\left[d_{1i} = d \mid d_{i}, n_{i}, n_{1i}, H_{0}\right] = \frac{\binom{d_{i}}{d} \binom{n_{i} - d_{i}}{n_{1i} - d}}{\binom{n_{i}}{n_{1i}}}$$

$$E\left[d_{1i} \mid d_i, n_i, n_{1i}, H_0\right] = n_{1i} \frac{d_i}{n_i} \qquad Var\left[d_{1i} \mid d_i, n_i, n_{1i}, H_0\right] = n_{1i} \frac{d_i}{n_i} (1 - \frac{d_{d_i}}{n_i}) \frac{n_i - n_{1i}}{n_i - 1}$$

Test statistic

Incorporating information from k 2 x 2 contingency tables

$$U = \sum_{i=1}^{k} \left(d_{1i} - e_{1i} \right)$$

$$e_{1i} = E\left[d_{1i} \mid d_i, n_i, n_{1i}, H_0\right] = n_{1i} \frac{d_i}{n_i}$$

$$E\left[U|H_0\right] = 0$$

$$v_{1i} = Var \left[d_{1i} | d_i, n_i, n_{1i}, H_0 \right]$$

$$Var\left[U|H_{0}\right] = \sum_{i=1}^{k} v_{1i}$$

$$= n_{1i} \frac{d_i}{n_i} \left(1 - \frac{d_{d_i}}{n_i} \right) \frac{n_i - n_{1i}}{n_i - 1}$$

Log-rank test

For large samples

$$Q = \frac{U - \overbrace{E(U)}^{=0}}{\sqrt{var(U)}} | H_0 \Rightarrow \text{Normal}(\mu = 0, \sigma = 1)$$

$$Q^* = \frac{U^2}{var(U)} | H_0 \rightsquigarrow \chi^2_{(1)}$$

Decision rule

$$p = P\left[Q^* > q_{obs} \mid H_0\right] \qquad \qquad \begin{cases} \text{do not reject } H_0, & \text{if } p > \alpha \\ & \text{reject } H_0, & \text{otherwise} \end{cases}$$

Exercise 1: rituximab clinical trial data

Compared with the survival curves for men versus women using log-rank (survdiff function from survival package)

Draw your conclusions.

Non-parametric methods

Comparison of different survival curves


Log-rank test Peto-Peto test

Semi-parametric regression

Cox's proportional hazard model


What type of incomplete data?

End of study



Begin of study

What type of incomplete data?



Begin of study End of study

Exercise 2: rituximab clinical trial data

Identify and quantify censored data concerning time to treatment response

Should you consider interval censoring in this case?

Basic mathematical formulation of the problem

Right/left censored data

$$\{t_i, d_i\}, i = 1, ..., n$$

$$\mathsf{t}_i = \begin{cases} t_i^*, & \text{if } t_i \text{ is right censored} \\ t_i, & \text{if } t_i \text{ is completely observed} \end{cases}$$

$$\mathbf{t}_{i} = \begin{cases} t_{i}^{+}, & \text{if } t_{i} \text{ is left censored} \\ t_{i}, & \text{if } t_{i} \text{ is completely observed} \end{cases}$$

Interval censored data

$$\{a_i, b_i, d_i\}, i = 1, ..., n$$

$$\mathbf{a}_{i} = \begin{cases} t_{i}^{*}, & \text{if } t_{i} \text{ is interval censored} \\ t_{i}, & \text{if } t_{i} \text{ is completely observed} \end{cases}$$

$$b_i = \begin{cases} t_i^+, & \text{if } t_i \text{ is interval censored} \\ t_i, & \text{if } t_i \text{ is completely observed} \end{cases}$$

$$d_i = \begin{cases} 0, & \text{if } t_i \text{ is censored} \\ 1, & \text{if } t_i \text{ is completely observed} \end{cases}$$

In practice

Package survival

Survival time

$$\text{time}_i = \begin{cases} t_i^*, & \text{if } t_i \text{ is right or interval censored} \\ t_i, & \text{if } t_i \text{ is completely observed} \\ t_i^+, & \text{if } t_i \text{ is left censored} \end{cases}$$

$$t_i \in \left(t_i^*, t_i^+\right)$$

$$time2_i = \begin{cases} t_i^+, & \text{if } t_i \text{ is interval censored} \\ 0, & \text{otherwise} \end{cases}$$

Event indicator

$$d_i = \begin{cases} 0, & \text{if } t_i \text{ is right censored} \\ 1, & \text{if } t_i \text{ is completely observed} \\ 2, & \text{if } t_i \text{ is left censored} \\ 3, & \text{if } t_i \text{ is interval censored} \end{cases}$$

Likelihood function of a parametric model under different censoring mechanisms

$$T_i \mid \theta \rightsquigarrow F(\theta)$$

Weibull, Gamma, Lognormal, Log-logistic, etc

Right censored data

$$L\left(\theta \mid \left\{t_i, d_i\right\}\right) \equiv \prod_{i=1}^n f_{\theta}(t_i)^{d_i} S_{\theta}(t_i)^{1-d_i}$$

Left censored data

$$L\left(\theta \mid \left\{t_i, d_i\right\}\right) \equiv \prod_{i=1}^n f_{\theta}(t_i)^{d_i} F_{\theta}(t_i)^{1-d_i}$$

Interval censored data

$$L\left(\theta \mid \left\{a_i, b_i, d_i\right\}\right) \equiv \prod_{i=1}^n f_{\theta}(a_i)^{d_i} \left(F_{\theta}(b_i) - F_{\theta}(a_i)\right)^{1 - d_i}$$

Parametric estimation

$$\hat{\theta} = \underset{\theta}{\operatorname{argmax}} L\left(\theta \mid \left\{t_{i}, d_{i}\right\}\right)$$

No closed-form expressions

Numerical solutions for the maximum likelihood equations

Exercise: rituximab clinical trial data

Estimate lognormal, weibull and log-logistic model to data on time to treatment response using the "survreg" function of package survival.

What is the best model for the data?

Checking the adequacy of a parametric model

Can we use the Kolmogorov-Smirnov test directly to data?

Kaplan-Meier estimator for the survival function

Non-parametric estimation of the cumulative probability distribution

Empirical cumulative probability distribution

Only completely observed or end-time censored data

Kaplan-Meier estimator

Data with (random) censored observations

Kaplan-Meier estimator for the survival function

$$\hat{S}(t) = \prod_{i:t_{i} \in \mathcal{S}} \left(1 - \frac{d_{i}}{n_{i}} \right) \qquad t \in (0, t_{\text{max}})$$

 d_i = number of individuals in which the event was observed at $t_{(i)}$

 n_i = number of individuals without the event of interest at $t_{(i-1)}$

 $\{t_{(i)}, i=1,...,r\}$ = unique times when the event of interest was observed

Kaplan-Meier estimator for the survival function

$$\hat{S}\left(t_{(1)}\right) = 1 - \frac{d_1}{n_1}$$

 n_1 = number of individuals without the event of interest at time 0 = n

$$\hat{S}\left(t_{(i)}\right) = \hat{S}\left(t_{(i-1)}\right) \left(1 - \frac{d_i}{n_i}\right)$$

Exercise 3: rituximab clinical trial data

Estimate the survival curve of time to treatment response using the Kaplan-Meier estimator

Compare the Kaplan-Meier estimated survival curve to the survival curve predicted by the best parametric model from Exercise 2.